Subject: Press Release Syngene International Announces ... · Commenting on the collaboratio n, Dr....
3
Ref: Syn/CS/SE/PR/May 2018 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, India T +91 80 6775 8000 F +91 80 6775 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com May 30, 2018 To, To, The Manager Listing The Manager Listing BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Corporate Communication Department Dalal Street, Mumbai – 400 001 Bandra (EAST), Mumbai – 400 051 Scrip Code: 539268 Scrip Symbol: SYNGENE Dear Sir/Madam, Subject: Press Release This has reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Please find enclosed the press release titled “Syngene International Announces Partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services ”. The above mentioned press release will also be available on website of the Company www.syngeneintl.com. This is for your information and records. Thanking You, Yours faithfully, For SYNGENE INTERNATIONAL LIMITED ____________ Mayank Verma Company Secretary
Transcript of Subject: Press Release Syngene International Announces ... · Commenting on the collaboratio n, Dr....
Ref: Syn/CS/SE/PR/May 2018 Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099, India
T +91 80 6775 8000
F +91 80 6775 8808
CIN: L85110KA1993PLC014937 www.syngeneintl.com
May 30, 2018
To, To,
The Manager Listing The Manager Listing
BSE Limited National Stock Exchange of India Limited
Corporate Relationship Department Corporate Communication Department
Dalal Street, Mumbai – 400 001 Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268 Scrip Symbol: SYNGENE
Dear Sir/Madam,
Subject: Press Release
This has reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations 2015, Please find enclosed the press release titled “Syngene International Announces
Partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services ”.
The above mentioned press release will also be available on website of the Company
www.syngeneintl.com.
This is for your information and records.
Thanking You,
Yours faithfully,
For SYNGENE INTERNATIONAL LIMITED
____________
Mayank Verma
Company Secretary
Putting Science to Work
PRESS RELEASE
Syngene International Announces Partnership with
Zumutor Biologics for Biotherapeutic Antibody
Discovery Services 30th May, 2018, Bengaluru, India and Boston, USA
Syngene International, a leading global Contract Research Services Company, has entered into
a non-exclusive partnering agreement with Zumutor Biologics, an emerging immuno-
oncology Company, to access Zumutor’s proprietary naïve human phage/yeast display library.
This collaboration further enhances Syngene’s market-leading capabilities in Discovery
Biology, providing its scientists with additional tools to help solve complex biology problems
in biotherapeutic drug discovery.
Under the terms of the agreement, Syngene will screen target antigens against Zumutor’s
proprietary human antibody libraries to identify and characterize novel antibody clones,
which will be further developed by Syngene towards novel biotherapeutics programs for its
partners.
Kavitha Iyer Rodrigues, Founder-CEO, Zumutor Biologics said, “Zumutor will use its
proprietary antibody display platform to enhance Syngene’s discovery programmes. Our
antibody engineering expertise and experience enables us to optimize any lead to evolve into
a best-in-class differentiated molecule”
Commenting on the collaboration, Dr. Manoj Nerurkar, Chief Operating Officer, Syngene
International, said, " Syngene has been a pioneer in discovery research and we see Discovery
Biology as one of our growth drivers. This partnership will expand our existing portfolio of
therapeutic antibody discovery platforms for our clients”
About Zumutor Biologics: Zumutor Biologics Inc. is a leading Immuno Oncology Company
focusing on novel monoclonal antibody therapeutics against innate immunity targets.
Zumutor’s high diversity human antibody libraries serve as powerhouse for developing novel
monoclonal antibody therapeutics targeting various immuno oncology pathways. Their
product pipeline constitutes unique immuno-oncotherapeutics that target innate immunity
and regulate tumor micro environment. Zumutor’s lead candidate in Prostate cancer revealed
significant tumor reduction, when applied alone and in combination with check point inhibitor
in mouse efficacy study. For more details, visit www.zumutor.com
About Syngene: Syngene International Limited, (BSE code: 539268, NSE Id: SYNGENE, ISIN Id:
INE398R01022) is one of the largest and fastest growing Contract Research Organizations in
the world. The Company is committed to creating strong customer impact through its cutting
edge scientific capabilities and state-of-the art research and manufacturing infrastructure. It
Putting Science to Work
provides integrated discovery and development services across multiple technology
platforms including small molecules, large molecules, Antibody-Drug Conjugates and
Oligonucleotides under an environment of high regulatory compliance and safety. Syngene
serves over 300 clients in the pharma, biotechnology, nutrition, animal health, consumer
goods and specialty chemicals industries, including 8 of the top 10 global pharma companies.
Its innovation driven culture and a strong team of over 3500 scientists, help R&D focused
organizations improve productivity and performance while shortening the development time
and cost. For more details or to see how Syngene can support your innovation, visit
www.syngeneintl.com.
For further information, please reach out to:
Zumutor Syngene International
Investor Contact
Kavitha Iyer Rodrigues
Cell (India): +91- 9845597393
Cell (US): +1(267) 370 6267
Chanderlekha Nayar
Ph: +91 80 6775 8821
Cell: +91 7259192001
Media Contact
Kavitha Iyer Rodrigues
Cell (India): +91- 9845597393
Cell (US): +1(267) 370 6267
Sandeep Nair
Ph: +91 80 6775 8775
Cell: +91 88843 67776
